GENEVA & DURHAM, N.C.--(BUSINESS WIRE)-- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and Aerie Pharmaceuticals, Inc. (NASDAQ: AERI, “Aerie”), a ...

Leveraging Alcon’s robust commercial capabilities and resources to drive further growth and access to Rocklatan and Rhopressa Acquisition adds pharmaceutical research and development capabilities and ...

Narrow-moat Alcon discussed current projects and initiatives, pipeline progression, and long-term financial goals in its 2025 Capital Markets Day. After digesting the performance of each business unit ...

Lifecore receives amendment and waiver for its term debt facility with Alcon and BMO CHASKA, Minn., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) ("Lifecore" or the ...

I reiterate a 'Strong Buy' rating for Alcon with a one-year price target of $115 per share, driven by new product pipelines and FDA clearances. Alcon's Unity VCS/CS systems received FDA clearance, set ...

Alcon reported fourth-quarter sales growth of 8.6% and core diluted EPS growth of 4.5%, both shy of FactSet consensus estimates. Guidance for 2026 includes 6% and 10.5% growth in constant currency for ...

Alcon Laboratories, already one of the largest employers and taxpayers in Tarrant County, is exploring a major expansion of its Fort Worth campus. Alcon, which started in Fort Worth and has grown to ...